UNIQURE Q3 Loss Widens - Quick Facts

(RTTNews) - UNIQURE N.V. (QURE) reported a third-quarter net loss of 9.06 million euros, compared to a loss of 7.04 million euros, prior year. Loss per share was 0.51 euros, compared to a loss of 0.61 euros.

Total revenues decreased year-over-year to 1.0 million euros from 1.3 million euros.

Jörn Aldag, uniQure CEO, said: "uniQure continues to direct key resources toward advancing the Company's core programs, most prominently hemophilia B, where we expect to announce preliminary safety and efficacy data in mid-2015, and our earlier-staged hemophilia A and congestive heart failure preclinical development programs."